Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | EYA2 | O00167 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11684972 | 1.00 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL22901 | 1.00 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL831877 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL456632 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL5067266 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL23859106 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL7541607 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL456238 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL15413556 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL7200211 | 0.98 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777831-B1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED LTD (IL) | 2023-11-29 | — | — | EP | disclosed |
| US-11660327-B2 | Methods and compositions for oral administration of proteins | ORAMED LTD. (IL) | 2023-05-30 | — | — | US | disclosed |
| EP-4025240-A1 | IL-22 ORAL, INTRA-RECTAL, OR OTHER GUT-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220160839-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2022-05-26 | — | — | US | disclosed |
| US-20220151919-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION | ENTERA BIO LTD. (IL) | 2022-05-19 | — | — | US | disclosed |
| US-11246827-B2 | Methods and compositions for oral administration | ENTERA BIO LTD. (IL) | 2022-02-15 | — | — | US | disclosed |
| US-20210322305-A1 | Methods and Compositions for Oral Administration of Exenatide | ORAMED LTD. (IL) | 2021-10-21 | — | — | US | disclosed |
| US-20210113663-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED LTD. (IL) | 2021-04-22 | — | — | US | disclosed |
| WO-2021046133-A1 | IL-22 ORAL, INTRA-RECTAL, OR OTHER GUT-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3777831-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Oramed Ltd. (IL) | 2021-02-17 | — | — | EP | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| EP-1001935-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 2000-05-24 | — | — | EP | disclosed |
| EP-0998564-A1 | MCP-1 ANALOGS | ZENECA LIMITED (GB) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007678-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999005279-A1 | MCP-1 ANALOGS | ZENECA LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
| EP-0703780-A4 | USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | UNIV SYDNEY (AU) | 1998-01-07 | — | — | EP | disclosed |
| EP-0703780-A1 | USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF SYDNEY (AU) | 1996-04-03 | — | — | EP | disclosed |
| US-4642284-A | BINDING AGENTS, LABELS, AGGREGATION, ASSAYING | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1987-02-10 | — | — | US | disclosed |
| EP-0128696-A2 | Method and apparatus for detection of complement pathway activation | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1984-12-19 | — | — | EP | disclosed |